Weberpals, J., Oza, A., Lorusso, D., Scambia, G., Aghajanian, C., Oaknin, A., Dean, A., Colombo, N., Clamp, A., Leary, A., Holloway, R., Amenedo Gancedo, M., Fong, P., Goh, J., O'Malley, D., Armstrong, D., Banerjee, S., García-Donas, J., Swisher, E., Cameron, T., Maloney, L., Goble, S., Coleman, R., & Ledermann, J. (n.d.). 3 Postprogression efficacy outcomes from the phase 3 ARIEL3 study of rucaparib in patients with platinum-sensitive recurrent ovarian carcinoma associated with either BRCA1 or BRCA2 mutations. International journal of gynecological cancer, 30, A2–A3. http://access.bl.uk/ark:/81055/vdc_100144717842.0x00001c